Concord Biotech
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Concord Biotech's recent developments indicate a strong commitment to innovation and growth, with management highlighting a 26% revenue increase in Q1FY27 and a 46% rise in exports. The successful ramp-up of the newly commissioned injectable facility and a focus on expanding the product pipeline are pivotal for future revenue growth. However, the company faces near-term challenges, including pricing pressures in the API segment and procurement delays, which could impact margins. Vista's financial outlook reflects these dynamics, projecting a recovery in revenue growth despite anticipated margin pressures. The company's strategic shift towards higher-margin segments and CDMO partnerships aligns with Vista's expectations for long-term value creation. Industry trends, particularly the increasing demand for Indian CDMOs amid global supply chain shifts, further support Concord's growth trajectory. Over the next 12-24 months, key opportunities include expanding into new geographies and deepening relationships with existing customers, while watchpoints include regulatory complexities and geopolitical tensions that may affect supply chains
Why We Like This Stock
- Strong revenue growth of 26% in Q1FY27 and a 46% increase in exports indicate robust demand
- Successful ramp-up of the injectable facility and a focus on new product launches are expected to enhance revenue streams
- Strategic shift towards higher-margin segments and CDMO partnerships positions the company for long-term value creation
Things To Watch Out For
- Pricing pressures in the API segment and procurement delays may impact margins in the short term
- Regulatory complexities and geopolitical tensions could disrupt supply chains and affect sales
- The need for continuous compliance in fermentation manufacturing adds operational challenges
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,017 | 1,200 | 1,055 | 1,268 | 1,497 |
| Profit Before Tax (Cr.) | 399 | 473 | 354 | 441 | 516 |
| PBT Margin | 39.2% | 39.4% | 33.6% | 34.8% | 34.5% |
| Net Profit (Cr.) | 303 | 359 | 264 | 329 | 386 |
| Earnings Per Share | 28.9 | 34.3 | 25.2 | 31.5 | 36.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Kotak Securities | ► Add | 1,400 | 30-Jun-2026 |
| Jeffries | ► Hold | 1,020 | 02-Jun-2026 |
| Citigroup | ► Add | 1,190 | 20-Apr-2026 |
Company Overview
Show Company Profile
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.